Seaport Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 year.
- Recent price momentum is -24.9% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 7.0% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 18.32
- Open
- 18.02
- Day range
- 17.41 - 18.83
- Avg price
- 18.13
- Volume
- 284.27K
- Turnover
- 5.15M
- Turnover ratei
- 1.53%
- Volume ratioi
- 0.70
- Amplitudei
- 7.77%
- 52-week rangei
- 14.85 - 28.38
Valuation
- P/Ei
- -12.78
- P/E (TTM)i
- -6.97
- P/Bi
- 2.43
- EPSi
- -1.41
- Book value / shi
- 7.43
- Net profit
- -75.59M
- Net assets
- 397.46M
Share structure
- Market cap
- 966.23M
- Float capi
- 334.46M
- Shares out
- 53.53M
- Float sharesi
- 18.53M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2026-05-01
36.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+363.97K net over the window
Short interest
- Shares short
- 3.73M
- % of floati
- 6.97%
- Days to coveri
- 17.42
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Seaport Therapeutics (SPTX)?
Seaport Therapeutics last traded at 18.05. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Seaport Therapeutics's market cap?
About 966.23M.
What is the P/E ratio of Seaport Therapeutics?
The trailing twelve-month P/E is -6.97. The Valuation tab shows it against the stock's own five-year range.
Does Seaport Therapeutics pay a dividend?
Seaport Therapeutics does not currently pay a regular dividend.
Is Seaport Therapeutics a buy according to analysts?
The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 37.43, which implies 107.4% upside from the current price. This is not investment advice.
What is Seaport Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Seaport Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Seaport Therapeutics discussion 0 comments